VTGN VistaGen Therapeutics Inc.

1.62
-0.01  -1%
Previous Close 1.63
Open 1.61
Price To Book 12.46
Market Cap 50312688
Shares 31,057,215
Volume 115,002
Short Ratio
Av. Daily Volume 603,622

SEC filingsSee all SEC filings

  1. 8-K/A [Amend] - Current report 181233814
  2. 8-K - Current report 181178005
  3. 8-K - Current report 181147404
  4. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181147307
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181144391

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due mid-2019.
AV-101
Adjunctive Treatment Major Depressive Disorder
Phase 2 trial to be completed 2H 2018.
AV-101
Monotherapy Treatment Major Depressive Disorder
Phase 2 trial to be initiated 1H 2019.
AV-101
Neuropathic pain
Phase 3 trial to be initiated 1H 2019.
PH94B nasal spray
Social Anxiety Disorder (SAD)

Latest News

  1. VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
  2. VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression
  3. VistaGen Therapeutics Reports Fiscal 2019 Second Quarter Financial Results
  4. Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more
  5. VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018
  6. VistaGen Therapeutics Appoints Dr. Michael Liebowitz to CNS Clinical and Regulatory Advisory Board in Preparation for Pivotal Phase 3 Development of PH94B as the First Rapid-Acting, On-Demand Treatment of Social Anxiety Disorder
  7. Tech and biotech on collision course, squeezed by the Peninsula's limited space
  8. VistaGen Up on Fast Track Designation to Pain Candidate
  9. Today’s Research Reports on Stocks to Watch: Pain Therapeutics and VistaGen Therapeutics
  10. VistaGen shares surge 13% after FDA grants fast track status to non-opioid pain treatment
  11. VistaGen Therapeutics Receives FDA Fast Track Designation for Development of AV-101 as a Non-Opioid Treatment for Neuropathic Pain
  12. SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating VistaGen Therapeutics, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
  13. Breakfast Technical Briefing on Tesaro and Three Other Additional Biotech Stocks

SEC Filings

  1. 8-K/A [Amend] - Current report 181233814
  2. 8-K - Current report 181178005
  3. 8-K - Current report 181147404
  4. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181147307
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181144391
  6. 8-K - Current report 181141848
  7. 8-K - Current report 181110156
  8. CT ORDER - Confidential treatment order 181096369
  9. D - Notice of Exempt Offering of Securities 181081546
  10. 8-K - Current report 181076474